Table 2. Comparison of recrudescence and metastasis risk between different FOXF2 mRNA levels and clinicopathological features in breast cancer patients.

Variables		Univariate analysis			Multivariate analysis
		OR	95% CI	P-value	OR	95% CI	P-value
Overall patients within 3-year follow up (n = 305)
Menopausal status	Pre. vs. post.	1.203	0.708–2.046	0.495
Tumor size (cm)	>2 vs. ≤2	2.020	1.019–4.003	0.044
LN status	Pos. vs. Neg.	3.440	1.736–6.818	<0.001	2.750	1.351–5.598	0.005
Clinical stage	III vs. I-II	3.484	2.027–5.989	<0.001	2.236	1.234–4.053	0.008
Histological grade	III vs. I-II	1.479	0.763–2.868	0.247
FOXF2 mRNA	Low vs. High	1.715	1.015–2.897	0.044
Grade II patients in overall follow up time (n = 226)
Menopausal status	Pre. vs. post.	1.181	0.730–1.909	0.498
Tumor size (cm)	>2 vs. ≤2	2.492	1.301–4.775	0.006	2.127	1.063–4.253	0.033
LN status	Pos. vs. Neg.	3.118	1.703–5.711	<0.001	2.798	1.456–5.377	0.002
Clinical stage	III vs. I-II	3.172	1.915–5.253	<0.001	2.144	1.239–3.710	0.006
FOXF2 mRNA	Low vs. High	1.676	1.038–2.706	0.035
Triple-negative patients in overall follow up time (n = 39)
Menopausal status	Pre. vs. post.	1.764	0.567–5.490	0.327
Tumor size (cm)	>2 vs. ≤2	5.135	0.663–39.798	0.117
LN status	Pos. vs. Neg.	13.723	1.765–106.704	0.012
Clinical stage	III vs. I-II	7.390	2.307–23.670	0.001	6.788	2.043–22.554	0.002
Histological grade	III vs. I-II	0.280	0.036–2.175	0.224
FOXF2 mRNA	Low vs. High	7.409	1.620–33.881	0.010	6.775	1.467–31.287	0.014